Research programme: anti-viral therapeutics - MicroQuin Therapeutics
Latest Information Update: 26 Aug 2021
At a glance
- Originator MicroQuin
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Adenovirus infections; COVID 2019 infections; Influenza virus infections; Respiratory syncytial virus infections
Most Recent Events
- 26 Aug 2021 Pharmacodynamics data from preclinical trial in Infections released by MicroQuin Therapeutics
- 24 Aug 2021 MicroQuin Therapeutics and National Institute of Allergy and Infectious Diseases collaborate to evaluate therapeutics for viral infections
- 24 Aug 2021 Preclinical trials in Adenovirus infections in USA (unspecified route) before August 2021